If Plus cannabis gummies are a big hit, just think how consumers will respond to hemp-derived CBD gummies.
It might not be time to panic yet about Tilray, but there's likely a problem ahead.
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Investors looking for another hemp play might consider Charlotte's Web Holdings, which deals in a range of CBD wellness products.
A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.
Apparently, this game is all about growth right now. It certainly is not about margins.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Let's check out the charts and indicators for this so-called pot play.
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Recently uplisted CTST is a huge player in the medical marijuana market.
You may want to check out GW Pharmaceuticals and Elixinol Global Limited.
This quarter is a heavy test for Tilray because of the stock's lofty valuation.
Assessing Aurora and its peers, strictly on the numbers.
Peltz's addition should pacify a persistent critique of the company.
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Aurora's prominent partner could be cannabis' key to breaking into consumer segments.
The plan is for Peltz to help the firm in maximizing potential markets to target.
Themes like cannabis tend to persist longer than many think they will.
The price of ACB is moving up today and a fresh look at the charts and indicators seems like a good idea.
Aurora's addition of a big name activist is accelerating share growth.
This $12 billion industry could rise to around $630 billion over time, according to Seaport analysts.
Potential buyers are faced with a small dilemma here.
Strength in Apple and other FANG names are pluses, as are pockets of action in gold mining, cannabis, biotechnology and shipping.
In its first report on cannabis companies, Melius says prices are high.
And the winners so far outnumber the losers among the six stocks that include a cannabis company, a couple financial giants and two oil plays.
The stock price of the cannabis company has been on a roll and is poised to move even higher still.
My trading strategy for GWPH whether you are currently long or want to be.
And why I won't recommend any other stocks in these markets, right now.
CLS Holdings USA has won a speculative buy rating from Canaccord, but the cannabis company will have to raise $56 million to complete some key acquisitions in order to keep it.